PI3Kβ Inhibitor TGX221 Selectively Inhibits Renal Cell Carcinoma Cells with Both VHL and SETD2 mutations and Links Multiple Pathways. This evidence concerns the gene SETD2 and hereditary clear cell renal cell carcinoma.